Fig. 2From: Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studiesrhGH dose per 6-month period by indication and pre-treatment status for GHD (a) and SGA (b) patients in the safety population enrolled in PATRO Children. GHD growth hormone deficiency, rhGH recombinant human growth hormone, SGA small for gestational ageBack to article page